

# Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](http://FDI Lab - SciCrunch.org) on Apr 8, 2025

## MI-Luciferase-IRES-mCherry

RRID:Addgene\_75020

Type: Plasmid

---

### Proper Citation

RRID:Addgene\_75020

---

### Plasmid Information

**URL:** <http://www.addgene.org/75020>

**Proper Citation:** RRID:Addgene\_75020

**Insert Name:** firefly Luciferase

**Organism:** Other

**Bacterial Resistance:** Ampicillin

**Defining Citation:** [PMID:24786772](https://pubmed.ncbi.nlm.nih.gov/24786772/)

**Vector Backbone Description:** Backbone Size:5500; Vector Backbone:MIGR1; Vector Types:Retroviral, Luciferase; Bacterial Resistance:Ampicillin

**Plasmid Name:** MI-Luciferase-IRES-mCherry

**Record Creation Time:** 20220422T222456+0000

**Record Last Update:** 20220422T224901+0000

---

### Ratings and Alerts

No rating or validation information has been found for MI-Luciferase-IRES-mCherry.

No alerts have been found for MI-Luciferase-IRES-mCherry.

---

### Data and Source Information

Source: [Addgene](#)

---

## Usage and Citation Metrics

We found 5 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [FDI Lab - SciCrunch.org](#).

Gammelgaard OL, et al. (2024) Adoptive cell transfer therapy with ex vivo primed peripheral lymphocytes in combination with anti-PDL1 therapy effectively inhibits triple-negative breast cancer growth and metastasis. *Molecular cancer*, 23(1), 6.

Zhang AQ, et al. (2023) Universal redirection of CAR T cells against solid tumours via membrane-inserted ligands for the CAR. *Nature biomedical engineering*, 7(9), 1113.

Yabushita T, et al. (2023) Mitotic perturbation is a key mechanism of action of decitabine in myeloid tumor treatment. *Cell reports*, 42(9), 113098.

Marone R, et al. (2023) Epitope-engineered human hematopoietic stem cells are shielded from CD123-targeted immunotherapy. *The Journal of experimental medicine*, 220(12).

Haugh KA, et al. (2021) In vivo imaging of retrovirus infection reveals a role for Siglec-1/CD169 in multiple routes of transmission. *eLife*, 10.